4D Molecular Therapeutics (FDMT) Net Margin (2020 - 2025)
Historic Net Margin for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to 63195.56%.
- 4D Molecular Therapeutics' Net Margin rose 13982377800.0% to 63195.56% in Q3 2025 from the same period last year, while for Sep 2025 it was 174314.17%, marking a year-over-year increase of 6696858300.0%. This contributed to the annual value of 434778.38% for FY2024, which is 4342917800.0% down from last year.
- As of Q3 2025, 4D Molecular Therapeutics' Net Margin stood at 63195.56%, which was up 13982377800.0% from 364386.67% recorded in Q2 2025.
- In the past 5 years, 4D Molecular Therapeutics' Net Margin registered a high of 169910.53% during Q4 2023, and its lowest value of 4967100.0% during Q4 2024.
- Its 5-year average for Net Margin is 416963.33%, with a median of 12391.63% in 2023.
- As far as peak fluctuations go, 4D Molecular Therapeutics' Net Margin tumbled by 2000000000bps in 2024, and later soared by 2000000000bps in 2025.
- Over the past 5 years, 4D Molecular Therapeutics' Net Margin (Quarter) stood at 27264.13% in 2021, then surged by 92bps to 2195.59% in 2022, then skyrocketed by 7839bps to 169910.53% in 2023, then crashed by -3023bps to 4967100.0% in 2024, then surged by 99bps to 63195.56% in 2025.
- Its Net Margin was 63195.56% in Q3 2025, compared to 364386.67% in Q2 2025 and 342657.14% in Q1 2025.